search
Back to results

Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases

Primary Purpose

Major Depressive Disorder

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
real-time fMRI neurofeedback: Amygdala
real-time fMRI neurofeedback: HIPS
Sponsored by
Laureate Institute for Brain Research, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Major Depressive Disorder focused on measuring Depression, Neurofeedback, Amygdala

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • clinical diagnosis of major depressive disorder
  • right handed
  • adult aged 18-55
  • currently depressed

Exclusion Criteria:

  • clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder
  • met Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for alcohol and/or substance abuse or substance dependence (other than nicotine) within 12 months prior to screening
  • endorse suicidal intent or have made a suicide attempt within the preceding three months
  • history of traumatic brain injury
  • inability to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body)
  • current pregnancy or breast feeding
  • a primary language other than English
  • received psychotropic drugs for at least 3 weeks (8 weeks for fluoxetine) prior to scanning (Effective medications will not be discontinued for the purposes of the study)

Sites / Locations

  • Laureate Institute for Brain Research

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

real-time fMRI neurofeedback: Amygdala

real-time fMRI neurofeedback: HIPS

Arm Description

Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.

HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.

Outcomes

Primary Outcome Measures

Change From Baseline in Montgomery Asberg Depression Rating Scale at 2 Weeks
Depression symptom severity rating scale. The overall score ranges on MADRS are from from 0 to 60, with higher scores indicating more severe depression. Usual cutoff points are: 0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression

Secondary Outcome Measures

Change From Baseline Beck Depression Inventory at 2 Weeks
Depression symptom severity rating scale. The overall score ranges on BDI are from from 0 to 63, with higher scores indicating more severe depression. Usual cutoff points are: 0 to 13 - normal /symptom absent 14 to 19 - mild depression 20 to 28 - moderate depression >29 - severe depression
Change From Baseline Hamilton Rating Scale for Depression at 2 Weeks
Depression symptom severity rating scale. The overall score ranges on HDRS are from from 0 to 50, with higher scores indicating more severe depression. Usual cutoff points are: 0 to 7 - normal /symptom absent 8 to 16 - mild depression 17 to 23 - moderate depression >24 - severe depression

Full Information

First Posted
March 4, 2014
Last Updated
July 21, 2017
Sponsor
Laureate Institute for Brain Research, Inc.
Collaborators
National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT02079610
Brief Title
Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases
Official Title
Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
April 2014 (undefined)
Primary Completion Date
April 2016 (Actual)
Study Completion Date
April 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Laureate Institute for Brain Research, Inc.
Collaborators
National Institute of Mental Health (NIMH)

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine whether upregulating the left amygdala during positive autobiographical memory recall via real time functional magnetic resonance imaging neurofeedback will lead to an improvement in clinician administered ratings of depressive symptoms. The investigators predict that patients with major depressive disorder receiving left amygdala neurofeedback will increase their amygdala response during positive autobiographical memory recall compared to those receiving control feedback from a region not involved in emotional processing and that this ability will be associated with clinically significant improvement.
Detailed Description
Major depressive disorder (MDD) is the leading cause of years lived with disability worldwide. Traditional pharmacological and/or psychological interventions are ineffective in up to one-half of patients, and treatments (such as electroconvulsive therapy, vagus nerve stimulation, and deep brain stimulation) available for severely ill patients who do not respond to standard interventions are invasive, and associated with potentially significant side effects. Therefore, there is a need to explore and develop novel non-invasive treatments. One such non-invasive method is real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf), which allows a person to see and regulate the fMRI signal from his or her own brain. Emerging evidence suggests rtfMRI-nf has clinical utility in reducing symptoms of chronic pain, tinnitus, and Parkinson's disease. The goal of the current study is to leverage recent advances in rtfMRI-nf to determine whether this procedure can be adapted as treatment for MDD. While amygdala activity is exaggerated in response to negative stimuli in MDD, evidence further suggests that the amygdala response to positive stimuli is attenuated in MDD and normalizes with remission. Therefore, the target for our rtfMRI-nf procedure is the left amygdala. Participants will be randomly assigned to receive rtfMRI-nf from either the left amygdala or the left horizontal segment of the intraparietal sulcus (HIPS; a region not involved in emotional processing) and to increase the activity within that region to a target level by thinking of positive autobiographical memories. This neurofeedback condition will alternate with periods of rest and counting backwards in order to allow participants to disengage from memory contemplation. A final run without neurofeedback information will be included to determine whether participants can maintain the learned amygdala elevation during positive memory recall in the absence of neurofeedback. Participants will complete two sessions within a one-week period. Clinical ratings will be taken at the time of each scan to determine whether the amygdala rtfMRI-nf procedure results in improvement of depression symptoms, and changes within the emotional regulation network that occur with successful amygdala regulation will be examined. Furthermore, the investigators aim to determine whether the rtfMRI-nf procedure will alter assessments of emotional processing conducted within three days prior to, and following completion of, the rtfMRI-nf procedure. Specific Aim 1: In individuals with MDD, determine the degree to which rtfMRI-nf enhances voluntary control over neural activity in the amygdala, co-modulates other brain regions within the emotion regulation circuitry, and alters depressive symptom severity ratings. Hypothesis 1.1: MDD participants receiving rtfMRI-nf regarding blood oxygen-level dependent (BOLD) activity within their amygdala can learn to voluntarily regulate this activity in response to positive stimuli. MDD participants receiving rtfMRI-nf regarding left amygdala activity will demonstrate greater activity in this region while contemplating positive autobiographical memories (AMs) than MDD participants receiving rtfMRI-nf regarding BOLD activity in the left HIPS, a region not involved in emotion. Hypothesis 1.2: The investigators hypothesize enhancing control over the amygdala via rtfMRI-nf will increase connectivity strengths between the amygdala and prefrontal regions involved in modulating emotional behavior including the pregenual anterior cingulate cortex and ventromedial prefrontal cortex. Hypothesis 1.3: The investigators hypothesize participants showing the greatest enhancement of amygdala activity in response to rtfMRI-nf also will show the greatest improvement in depressive symptom severity ratings at the end of the study. Specific Aim 2: In MDD patients, determine the degree to which rtfMRI-nf from the amygdala restores a normative mood-congruent processing bias during the processing of emotionally valenced stimuli. Hypothesis 2.1: During the performance of a backward masking task in which emotional faces are presented below conscious awareness, the investigators hypothesize MDD participants will initially show a processing bias toward negative stimuli in the amygdala that will reverse to a processing bias toward positive stimuli in participants receiving active vs HIPS rtfMRI-nf Hypothesis 2.2: The investigators hypothesize that MDD patients will initially show a mood-congruent processing bias toward negative stimuli on the P1Vital Emotional Test Battery that will reverse to a bias toward positive stimuli following amygdala (vs HIPS) rtfMRI-nf. Results from this project will lead to new insights into the plastic neurobiological mechanisms that govern recovery from MDD and promote novel, non-invasive approaches to MDD treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder
Keywords
Depression, Neurofeedback, Amygdala

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
real-time fMRI neurofeedback: Amygdala
Arm Type
Experimental
Arm Description
Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
Arm Title
real-time fMRI neurofeedback: HIPS
Arm Type
Active Comparator
Arm Description
HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
Intervention Type
Behavioral
Intervention Name(s)
real-time fMRI neurofeedback: Amygdala
Intervention Description
Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
Intervention Type
Behavioral
Intervention Name(s)
real-time fMRI neurofeedback: HIPS
Intervention Description
Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
Primary Outcome Measure Information:
Title
Change From Baseline in Montgomery Asberg Depression Rating Scale at 2 Weeks
Description
Depression symptom severity rating scale. The overall score ranges on MADRS are from from 0 to 60, with higher scores indicating more severe depression. Usual cutoff points are: 0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression
Time Frame
baseline and 2 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline Beck Depression Inventory at 2 Weeks
Description
Depression symptom severity rating scale. The overall score ranges on BDI are from from 0 to 63, with higher scores indicating more severe depression. Usual cutoff points are: 0 to 13 - normal /symptom absent 14 to 19 - mild depression 20 to 28 - moderate depression >29 - severe depression
Time Frame
baseline and 2 weeks
Title
Change From Baseline Hamilton Rating Scale for Depression at 2 Weeks
Description
Depression symptom severity rating scale. The overall score ranges on HDRS are from from 0 to 50, with higher scores indicating more severe depression. Usual cutoff points are: 0 to 7 - normal /symptom absent 8 to 16 - mild depression 17 to 23 - moderate depression >24 - severe depression
Time Frame
baseline and 2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: clinical diagnosis of major depressive disorder right handed adult aged 18-55 currently depressed Exclusion Criteria: clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder met Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for alcohol and/or substance abuse or substance dependence (other than nicotine) within 12 months prior to screening endorse suicidal intent or have made a suicide attempt within the preceding three months history of traumatic brain injury inability to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body) current pregnancy or breast feeding a primary language other than English received psychotropic drugs for at least 3 weeks (8 weeks for fluoxetine) prior to scanning (Effective medications will not be discontinued for the purposes of the study)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kymberly D Young, PhD
Organizational Affiliation
Laureate Institute for Brain Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Laureate Institute for Brain Research
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74136
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
24223175
Citation
Zotev V, Phillips R, Young KD, Drevets WC, Bodurka J. Prefrontal control of the amygdala during real-time fMRI neurofeedback training of emotion regulation. PLoS One. 2013 Nov 6;8(11):e79184. doi: 10.1371/journal.pone.0079184. eCollection 2013.
Results Reference
background
PubMed Identifier
21931738
Citation
Zotev V, Krueger F, Phillips R, Alvarez RP, Simmons WK, Bellgowan P, Drevets WC, Bodurka J. Self-regulation of amygdala activation using real-time FMRI neurofeedback. PLoS One. 2011;6(9):e24522. doi: 10.1371/journal.pone.0024522. Epub 2011 Sep 8.
Results Reference
background
PubMed Identifier
24523939
Citation
Young KD, Zotev V, Phillips R, Misaki M, Yuan H, Drevets WC, Bodurka J. Real-time FMRI neurofeedback training of amygdala activity in patients with major depressive disorder. PLoS One. 2014 Feb 11;9(2):e88785. doi: 10.1371/journal.pone.0088785. eCollection 2014.
Results Reference
background
PubMed Identifier
28407727
Citation
Young KD, Siegle GJ, Zotev V, Phillips R, Misaki M, Yuan H, Drevets WC, Bodurka J. Randomized Clinical Trial of Real-Time fMRI Amygdala Neurofeedback for Major Depressive Disorder: Effects on Symptoms and Autobiographical Memory Recall. Am J Psychiatry. 2017 Aug 1;174(8):748-755. doi: 10.1176/appi.ajp.2017.16060637. Epub 2017 Apr 14.
Results Reference
derived

Learn more about this trial

Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases

We'll reach out to this number within 24 hrs